Special Issue "Protein Kinase in Leukemia"
Deadline for manuscript submissions: 31 March 2021.
Interests: oncogenic signaling; kinases; leukemia; targeted therapies; resistance; stem cells
Special Issues and Collections in MDPI journals
Interests: protein kinases; leukemia; signaling; membrane receptors; kinase inhibitors
Protein kinases are required to phosphorylate substrates on threonine, serine or tyrosine residues, allowing structural protein modification leading to enzyme activation or recruitments of signaling partners at docking sites, giving raise to signaling transduction pathways. About 500 human genes encode kinases. Kinase activity controls signaling pathways involved in many cellular processes, such as cell growth, proliferation, differentiation or metabolism. In hematopoiesis, many kinases play a key role at different steps of blood cell generation, and deregulation, through mutations, expression or location, often leads to malignancies. Among these, several chronic or acute leukemias are driven by deregulated kinases, for which recent decades have seen the development of targeted therapies. Although tyrosine phosphorylations represent only 0.1% of whole phosphorylation, deregulated tyrosine kinases are involved in a large number of oncogenic mechanisms.
Blocking kinase enzymatic activity has therefore become a quest for pharmaceutical companies. The paradigm of kinase targeting is remembered by the development of the first inhibitor FDA-approved in chronic myeloid leukemia (CML) treatment, imatinib.
Today, around 50 kinase inhibitors are FDA-approved, while at least 150 are being investigated in clinical trials.
Dr. Jean-Max Pasquet
Dr. Paulo De Sepulveda
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Oncogenic Signaling
- Targeted Therapies